Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis

Company Overview

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.01 to $0.13
• 52-Week Range: N/A
• Volume: 2.48 million shs
• Average Volume: 2.58 million shs
• Market Capitalization: $726,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INFI Stock Analysis - Frequently Asked Questions

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to analyst estimates of $0.45 million.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Infinity Pharmaceuticals investors own include Block (SQ), Digital Turbine (APPS), ChargePoint (CHPT), CrowdStrike (CRWD), Vuzix (VUZI) and Sangamo Therapeutics (SGMO).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INFI
• CUSIP: 45665G30
• CIK: 1113148
• Web: www.infi.com
• Phone: (617) 453-1000
• Fax: 617-453-1001
• Employees: 30
• Year Founded: 2000

Profitability

• EPS (Most Recent Fiscal Year): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-44,370,000.00
• Net Margins: -1,593.93%
• Pretax Margin: -1,593.93%
• Return on Equity: N/A
• Return on Assets: -113.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $2.59 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.21) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 90,760,000
• Free Float: 81,857,000
• Market Cap: $726,000.00
• Optionable: Optionable
• Beta: 1.63